Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Novavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference

NVAX

GAITHERSBURG, Md., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the Ladenburg Thalmann Healthcare 2015 Conference.

Conference details are as follows:

Date: Tuesday, September 29, 2015
Time: 1:30 – 1:55 p.m. US Eastern Time
Location: Sofitel Hotel, New York City
Live webcast: http://wsw.com/webcast/ladenburg/nvax

The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.

Contact:
Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000
               
Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com 
todd.davenport@russopartnersllc.com
212-845-4271  

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today